Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Other solid neoplasm 5Gastrointestinal 5Dermatologic 5Genitourinary 4CNS 3Head & Neck 2Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Endocrine 1Classical hematology 1Breast 1

Conditions

Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 94fludarabine phosphate 87Busulfan 64Cyclosporine 57Epoetin Alfa 55Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53fludarabine 45Antilymphocyte Serum 43Filgrastim 41Cytarabine 41Melphalan 40Tacrolimus 39Darbepoetin alfa 39Methotrexate 34Radiotherapy 33Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23apixaban 22Methylprednisolone 22Rivaroxaban 21Etoposide 21Thiotepa 17Dalteparin 17eltrombopag 16ferric carboxymaltose 14epoetin beta 14Daunorubicin 14Azacitidine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Semaxinib × Classical hematology × Clear all
NCT00005942 2013-01-23

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

National Cancer Institute (NCI)

Phase 1/2 Completed
37 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡